anti-CLDN6 antibody drug conjugate (ADC Therapeutics)

N/A

Report date: 2025/06/11 11:18:14

Base Information

Drug Nameanti-CLDN6 antibody drug conjugate (ADC Therapeutics)
Drug Alias NameGB01-VA-PL2202
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionClaudin 6 modulatorsDNA topoisomerase I inhibitors
TargetsClaudin 6DNA topoisomerase I
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAdc Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesAdc Therapeutics Sa
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A